CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

sacubitril/valsartan

Last Updated: September 14, 2020
Result type: Reports
Project Number: SR0644-000
Product Line: Common Drug Review

Generic Name: sacubitril/valsartan

Brand Name: Entresto

Manufacturer: Novartis Pharma Inc.

Indications: Heart failure, NYHA Class II or III

Manufacturer Requested Reimbursement Criteria1: Addition to the current criteria: Initiation of sacubitril/valsartan may be considered in patients stabilized from a heart failure hospitalization without prior exposure to angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB).

Submission Type: Resubmission

Project Status: Active

Fee Schedule: Schedule B

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMarch 30, 2020
Call for patient input closedMay 20, 2020
Clarification:

- Patient input submission received from The HeartLife Foundation

Submission receivedMay 22, 2020
Submission acceptedJune 05, 2020
Review initiatedJune 08, 2020
Draft CADTH review report(s) provided to sponsor for commentSeptember 02, 2020
Deadline for sponsors commentsSeptember 14, 2020
CADTH responses on draft review report(s) provided to sponsorOctober 08, 2020
Expert committee meeting (initial)October 21, 2020
Draft recommendation issuedNovember 02, 2020
To
November 04, 2020